Quidel Co. (NASDAQ:QDEL) SVP Michael Donald Jr. Abney sold 8,798 shares of Quidel stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $65.00, for a total transaction of $571,870.00. Following the sale, the senior vice president now owns 14,226 shares in the company, valued at $924,690. The sale was disclosed in a document filed with the SEC, which is available through this link.

NASDAQ:QDEL traded down $0.20 during midday trading on Thursday, hitting $68.42. 363,000 shares of the company were exchanged, compared to its average volume of 216,218. The company has a fifty day simple moving average of $59.85 and a 200 day simple moving average of $60.72. Quidel Co. has a fifty-two week low of $44.27 and a fifty-two week high of $74.78. The company has a current ratio of 1.40, a quick ratio of 0.83 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $2.89 billion, a PE ratio of 24.26, a price-to-earnings-growth ratio of 0.95 and a beta of 1.39.

Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The company had revenue of $108.25 million for the quarter, compared to analyst estimates of $108.40 million. Quidel had a net margin of 13.71% and a return on equity of 23.34%. Quidel’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.36 earnings per share. As a group, equities research analysts expect that Quidel Co. will post 2.69 EPS for the current year.

Several brokerages recently commented on QDEL. Zacks Investment Research lowered shares of Quidel from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 18th. Craig Hallum upgraded shares of Quidel from a “hold” rating to a “buy” rating and lifted their price target for the stock from $63.00 to $75.00 in a research note on Thursday, August 29th. ValuEngine upgraded shares of Quidel from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub lowered shares of Quidel from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, TheStreet lowered shares of Quidel from a “b” rating to a “c+” rating in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Quidel has a consensus rating of “Buy” and a consensus target price of $73.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of QDEL. Dimensional Fund Advisors LP increased its stake in Quidel by 2.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 861,159 shares of the company’s stock valued at $42,041,000 after purchasing an additional 17,041 shares during the period. Geode Capital Management LLC increased its stake in Quidel by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 387,877 shares of the company’s stock valued at $18,936,000 after purchasing an additional 27,954 shares during the period. Strs Ohio acquired a new position in Quidel in the first quarter valued at $58,000. BNP Paribas Arbitrage SA increased its stake in Quidel by 836.8% in the first quarter. BNP Paribas Arbitrage SA now owns 7,841 shares of the company’s stock valued at $513,000 after purchasing an additional 7,004 shares during the period. Finally, Bank of Montreal Can increased its stake in Quidel by 10.7% in the first quarter. Bank of Montreal Can now owns 26,822 shares of the company’s stock valued at $1,756,000 after purchasing an additional 2,584 shares during the period. Institutional investors own 91.04% of the company’s stock.

Quidel Company Profile

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

See Also: Strike Price

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.